Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00
8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
EFFECT - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced it has entered into a Common Stock Purchase Agreement for up to $500 million to establish an equity line of credit ("ELOC") and bolster its BNB cryptocurrency treasury strategy. The company also entered into an additional $20 million stock purchase agreement with Build and Build Corp. Ninety-ni
WARRINGTON, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is pleased to announce a strategic partnership with Kraken, a leading global cryptocurrency platform, to provide custody, trading, and over-the-counter (OTC) services for Windtree's BNB Crypto Treasury Strategy. The parties have signed a term sheet, to be memorialized in a definitive agreement following shareholder approval of Windtree's previously announced securities purchase agreement, with potential for up to an additional $140 million in future subscriptions, led by Build and Build Corp. This partnership positions Windtree to leverage Kraken's industry-leadi
WARRINGTON, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is excited to announce it has entered into a $60 million securities purchase agreement led by Build and Build Corp, with the potential for up to an additional $140 million in gross proceeds in future subscriptions, for total subscriptions of up to $200 million. The proceeds, expected to be in the form of cash, shares of Osprey BNB Chain Trust and BNB, from this financing, upon closing, is to be primarily used to launch a BNB crypto treasury strategy and purchase BNB, positioning Windtree as a leader in the BNB digital asset . Subject to shareholder approval and the
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment
WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors ("Board"). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. Ms. Kelly has served as GRI Bio's Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors w
WARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board. Mr. Fraser has ser
WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. "The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a revenue generating company by seeking to identify and acquire revenue-generating FDA-approved assets while advancing our cardiology and oncology pipeline," said Jed Latkin, Chief Executive
WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician
-- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E
SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)